drugset
drugset / Trial / NCT01505894

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses

NCT01505894 ↗

Phase 1 Completed 83 enrolled Boehringer Ingelheim
RandomizedSingle-groupDouble-blindTreatment

Summary

The primary objective of this trial was to investigate safety and tolerability of multiple doses of BI 409306 in healthy young and elderly volunteers. The secondary objective was to explore the pharmacokinetics and pharmacodynamics of multiple doses of BI 409306 in healthy young and elderly volunteers

Timeline

Start
2012-01-01
Primary completion
2012-07-01
Completion
2012-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject OSORESNONTRINE Small molecule 25 mg Oral
Subject OSORESNONTRINE Small molecule 50 mg Oral
Subject OSORESNONTRINE Small molecule 100 mg Oral

Indications

No indication recorded.